- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02803593
To Enhance Breast Cancer Survivorship of Asian Americans (TICAA)
June 28, 2022 updated by: Eun-Ok Im, Emory University
The purpose of this randomized intervention study is to test the efficacy of the technology-based information and coaching/support program for Asian American breast cancer survivors (TICAA) in enhancing the women's breast cancer survivorship experience.
Study Overview
Status
Completed
Conditions
Detailed Description
Despite few studies on Asian American breast cancer survivors, it is well known that these women shoulder unnecessary burden of breast cancer because they rarely complain about symptoms or pain, delay seeking help, and rarely ask or get support due to their cultural values and beliefs and language barriers.
This demonstrates a definite need for support in this specific population.
However, survivorship programs that are increasingly instituted at cancer centers have serious impediments to providing information and coaching/support because of the lack of staff time and insurance reimbursement.
Furthermore, the pressure of fast-paced clinical patient-provider interactions leaves little time for health care providers to provide up-to-date information and coaching or support for these women based on their cultural attitudes.
All these circumstances necessitate an innovative and creative delivery method of information and coaching/support.
A technology-based approach using computers and mobile devices (smart phones and tablets) promises to meet this necessity with high flexibility and accessibility, and minimizes the cost of the intervention in busy and costly health care settings.
Also, a technology-based intervention that does not involve face-to-face interactions could work better for many women from cultures where breast cancer is still a stigmatizing experience.
Therefore, based on preliminary studies, the research team has developed and pilot-tested a theory-driven technology-based information and coaching/support program that is culturally tailored to Asian American breast cancer survivors using multiple features.
The purpose of the proposed randomized intervention study is to test the efficacy of the technology-based information and coaching/support program for Asian American breast cancer survivors (TICAA) in enhancing the women's breast cancer survivorship experience.
The specific aims are to: a) determine whether the intervention group will show significantly greater improvements than the control group in primary outcomes (needs for help, physical and psychological symptoms, and quality of life) from baseline (pre-test) to Time Points 1 (post 1-month) and 2 (post 3-months); b) identify theory-based variables (attitudes, self-efficacy, perceived barriers, and social influences related to breast cancer survivorship) that mediate the intervention effects of the TICAA on the primary outcomes at the three time points (pre-test, post 1-month and post 3-months); and c) determine whether the effects of the TICAA on the primary outcomes are moderated by background characteristics and disease factors.
The proposed study will be guided by the Bandura's Theory of Behavioral Change.
This study adopts a randomized repeated measures pretest/posttest control group design in 330 Asian American breast cancer survivors.
The long-term goals are to: (a) implement the program into various health care settings; (b) determine if the TICAA will lead to long-term improved health outcomes; and (c) fundamentally enhance the methodology/paradigm of culturally tailored technology-based interventions for ethnic minority groups of breast cancer survivors.
Study Type
Interventional
Enrollment (Actual)
199
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Georgia
-
Atlanta, Georgia, United States, 30322
- Emory University Hospital
-
-
North Carolina
-
Durham, North Carolina, United States, 27710
- Duke University, School of Nursing
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
21 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Description
Inclusion Criteria:
- Self-reported Asian American women aged 21 years and older who identify their sub-ethnicity as Chinese, Korean, or Japanese
- Have had a breast cancer diagnosis
- Can read and write English, Mandarin Chinese, Korean or Japanese
- Have access to the Internet through computers or mobile devices (smart phones and tablets)
Exclusion Criteria:
- Those under 21 years old are excluded because their cancer experience would be different from adults
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Control
Asian American breast cancer survivors who do not use the TICAA, but use the information on breast cancer by the American Cancer Society (ACS).
Participants are asked to use the online ACS resources for 3 months.
|
The American Cancer Society (ACS) webpage has a wide range of information on breast cancer including prevention, treatment, and ways to connect with breast cancer survivors.
|
Experimental: TICAA Intervention
Asian American breast cancer survivors who use the TICAA intervention and the information by the ACS.
The intervention is a technology-based information and coaching/support program to enhance survivorship experience of Asian American breast cancer survivors.
Participants are asked to use the TICAA program for 3 months.
|
The American Cancer Society (ACS) webpage has a wide range of information on breast cancer including prevention, treatment, and ways to connect with breast cancer survivors.
The TICAA has three components in four languages (English, Mandarin Chinese, Korean, and Japanese): (a) social media sites; (b) interactive online educational sessions; and (c) online resources.
The social media sites provide a mechanism by which participants can receive coaching/support from culturally matched peers and health care providers.
The educational sessions provide information about general and sub-ethnic- specific topics related to breast cancer survivorship.
The online resources include 35 Web links to resources related to breast cancer survivorship from scientific authorities and from general and sub-ethnic-specific health organizations/institutes.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Support Care Needs Survey (SCNS) Score
Time Frame: Baseline, Month 1, Month 3
|
The SCNS uses 57 items to measure how much help the respondent needs.
Responses are given on a scale from 1 to 5 where 1 = no help is needed and 5 = high need for help.
Total scores range from 57 to 285 and higher scores indicate greater need for help.
|
Baseline, Month 1, Month 3
|
Memorial Symptom Assessment Scale-Short Form (MSAS-SF) Score
Time Frame: Baseline, Month 1, Month 3
|
Physical and psychological symptoms are assessed using the Memorial Symptom Assessment Scale-Short Form (MSAS-SF).
The MSAS-SF asks if the respondent has experienced any of 32 specific symptoms during the past week, with the opportunity for the participant to enter additional symptoms.
The degree of distress experienced by 28 of the symptoms is measured on a scale from 0 (not at all) to 4 (very much).
The total score is the average of the responses to the distress scale items and and ranges from 0 to 4 with higher values indicating greater distress experienced from symptoms.
|
Baseline, Month 1, Month 3
|
Functional Assessment of Cancer Therapy Scale-Breast Cancer (FACT-B) Score
Time Frame: Baseline, Month 1, Month 3
|
Quality of life is assessed using the FACT-B.
The FACT-B includes 41 items which are responded to on a scale from 0 to 4, where 0 = not at all and 4 = very much.
The total score ranges from 0 to 164 and higher scores indicate better quality of life.
|
Baseline, Month 1, Month 3
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Questions on Attitudes, Self-Efficacy, Perceived Barriers, and Social Influences (QASPS) Score for Attitudes
Time Frame: Baseline, Month 1, Month 3
|
Attitudes related to breast cancer survivorship are measured using the Questions on Attitudes, Self-Efficacy, Perceived Barriers, and Social Influences (QASPS).
The Attitudes section of this questionnaire includes 6 items scaled from -3 to 3, where -3 is the most negative score and 3 is the most positive score.
There are also 7 qualitative questions.
The total score for the scaled items ranges from -18 to 18 and higher scores indicate a better attitude towards breast cancer survivorship.
|
Baseline, Month 1, Month 3
|
Questions on Attitudes, Self-Efficacy, Perceived Barriers, and Social Influences (QASPS) Score for Perceived Barriers
Time Frame: Baseline, Month 1, Month 3
|
Perceived barriers related to breast cancer survivorship are measured using the Questions on Attitudes, Self-Efficacy, Perceived Barriers, and Social Influences (QASPS).
The Perceived Barriers section of this questionnaire includes 16 items where responses are given on a 4-point scale where 1 = never and 4 = always.
Total scores range from 16 to 64 and higher scores indicate greater perceived barriers related to breast cancer survivorship.
|
Baseline, Month 1, Month 3
|
Questions on Attitudes, Self-Efficacy, Perceived Barriers, and Social Influences (QASPS) Score for Social Influences
Time Frame: Baseline, Month 1, Month 3
|
Social influences related to breast cancer survivorship are measured using the Questions on Attitudes, Self-Efficacy, Perceived Barriers, and Social Influences (QASPS).
The Social Influences section of this questionnaire includes 3 items where responses are given on a 7-point scale where 1 = disapproval from social support and 7 = approval from social support.
Total scores range from 3 to 21 and higher scores indicate greater positive support from social influences.
|
Baseline, Month 1, Month 3
|
Cancer Behavior Inventory-Brief Version (CBI-B) Score
Time Frame: Baseline, Month 1, Month 3
|
Self-efficacy related to breast cancer survivorship is measured using the Cancer Behavior Inventory-Brief Version (CBI-B).
The CBI-B has 12 items assessing the degree of confidence respondents have with certain coping behaviors on a scale from 1 (not at all confident) to 9 (totally confident).
Total scores range from 12 to 108 where higher scores indicate greater self-efficacy concerning cancer behaviors.
|
Baseline, Month 1, Month 3
|
Personal Resource Questionnaire (PRQ-2000) Score
Time Frame: Baseline, Month 1, Month 3
|
The Personal Resource Questionnaire (PRQ-2000) is a 15-item survey asking how much participants agree or disagree with statements related to social resources on a scale from 1 (strongly disagree) to 7 (strongly agree).
Total scores range from 15 to 105 and higher scores indicate greater social resources.
|
Baseline, Month 1, Month 3
|
Perceived Isolation Scale (PIS) Score
Time Frame: Baseline, Month 1, Month 3
|
The Perceived Isolation Scale (PIS) includes 9 items asking questions about how social connectedness.
Responses are rated on a 3-point scale where 1 = hardly ever, 2 = some of the time, and 3 = often.
The total score is the average of the responses to the PIS items and ranges from 1 to 3 with lower scores indicating greater social connectedness.
|
Baseline, Month 1, Month 3
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Eun-Ok Im, PhD, MPH, Emory University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
June 1, 2016
Primary Completion (Actual)
June 9, 2021
Study Completion (Actual)
June 9, 2021
Study Registration Dates
First Submitted
June 14, 2016
First Submitted That Met QC Criteria
June 14, 2016
First Posted (Estimate)
June 17, 2016
Study Record Updates
Last Update Posted (Actual)
June 29, 2022
Last Update Submitted That Met QC Criteria
June 28, 2022
Last Verified
June 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- IRB00117270
- R01CA203719-01 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer
-
Northwestern UniversityEisai Inc.UnknownMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative...United States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyActive, not recruitingStage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of WashingtonTerminatedBreast Cancer | Breast Cancer Stage I | Breast Cancer Stage II | Breast Cancer Stage III | Breast Cancer Stage IIB | Breast Cancer Stage IIA | Breast Cancer Stage IIIA | Breast Cancer Stage IIIB | Breast Cancer Stage IIIcUnited States
-
CelgeneCompletedBreast Cancer | Metastatic Breast Cancer | Stage IV Breast Cancer | Triple-negative Breast Cancer | Recurrent Breast Cancer | Breast Tumor | Cancer of the Breast | Triple-negative Metastatic Breast Cancer | Estrogen Receptor- Negative Breast Cancer | HER2- Negative Breast Cancer | Progesterone Receptor- Negative...United States, United Kingdom, Italy, Germany, Spain, Canada, Portugal, Australia, Austria, Greece, Brazil, France
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedHER2-positive Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Estrogen Receptor-negative Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-negative Breast Cancer | Progesterone Receptor-positive Breast...United States
-
Baylor Breast Care CenterRecruitingBreast Cancer | Breast Neoplasm | Triple Negative Breast Cancer | Triple Negative Breast Neoplasms | HER2-positive Breast Cancer | Breast Cancer Stage II | Breast Cancer Female | Breast Cancer Stage III | Estrogen Receptor-positive Breast Cancer | Hormone Receptor-positive Breast Cancer | Breast Cancer InvasiveUnited States
-
Innocrin PharmaceuticalCompletedBreast Cancer | Advanced Breast Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | Male Breast Cancer | ER+ Breast Cancer | Cancer of the BreastUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Male Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
Clinical Trials on American Cancer Society information on breast cancer
-
Pontificia Universidad Catolica de ChileComisión Nacional de Investigación Científica y TecnológicaRecruitingBreast Cancer | Breast Tumor | Mammary Cancer | Mammary TumorChile
-
Stanford UniversityUniversity of California, BerkeleyCompletedDepression | Breast Cancer | Stress Disorders, Post-traumaticUnited States
-
Northeastern UniversityAmerican Physical Therapy AssociationCompletedBreast Cancer
-
Northwestern UniversityLynn Sage Breast Cancer Research FoundationCompletedBreast Cancer Female
-
Memorial Sloan Kettering Cancer CenterActive, not recruitingBreast CancerUnited States
-
Gazi UniversityNot yet recruitingGrief | Posttraumatic Growth
-
Washington University School of MedicineNational Institute on Minority Health and Health Disparities (NIMHD)CompletedOncology | Breast Cancer Screening | Mammography | Preventative MedicineUnited States
-
First Affiliated Hospital, Sun Yat-Sen UniversityThe First Affiliated Hospital with Nanjing Medical University; Peking University... and other collaboratorsRecruiting
-
Centre Leon BerardThe Biostatistics and Therapy Evaluation Unit; BEC (Department of Clinical...CompletedBreast Cancer | Lung CancerFrance
-
Stanford UniversityUniversity of California, BerkeleyCompletedDepression | Breast Cancer | Stress Disorders, Post-TraumaticUnited States